The use of sodium oxybate to treat narcolepsy.

Abstract:

:Narcolepsy is a life-long neurodegenerative disorder that causes considerable impairment to quality of life. Until the 1970s, the treatment for one of the main symptoms, excessive daytime sleepiness, was restricted to stimulants, whereas the second core symptom, cataplexy, was treated with antidepressants, and the resultant fragmented night-time sleep with hypnotics. Sodium oxybate (Xyrem(®), UCB Pharma, Brussels, Belgium) is an efficacious drug for all three symptoms which improves the quality of life of narcoleptic patients. Owing to its metabolic pathway, there is very little pharmacokinetic interaction with other drugs. In combination with modafinil, some of its therapeutic benefits are enhanced. Adverse events and side effects are moderate when taken according to indication and as recommended. Essential limitations have to be considered before starting the treatment (sleep-related breathing disorders, alcohol intake, hypnotic and sedative comedication, and epilepsy). This article gives an overview of sodium oxybate, which has been US FDA approved for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy, and EMA approved for the treatment of narcolepsy-cataplexy.

journal_name

Expert Rev Neurother

authors

Mayer G

doi

10.1586/ern.12.42

subject

Has Abstract

pub_date

2012-05-01 00:00:00

pages

519-29

issue

5

eissn

1473-7175

issn

1744-8360

journal_volume

12

pub_type

杂志文章,评审
  • Progress in imaging the effects of psychosis susceptibility gene variants.

    abstract::Genetic imaging has become an increasingly popular tool that utilizes neuroimaging techniques to investigate the impact of genetic variation on the structure, function and connectivity of the brain. Combining genetic and neuroimaging domains is a promising approach to further the understanding of the neural mechanisms...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.145

    authors: Redpath HL,Lawrie SM,Sprooten E,Whalley HC,McIntosh AM,Hall J

    更新日期:2013-01-01 00:00:00

  • Cannabis and multiple sclerosis.

    abstract:INTRODUCTION:Patients with multiple sclerosis (MS) may suffer from spasticity and pain during their disease course. Baclofen, dantrolene, diazepam and gabapentin have been used as first-line options to treat these conditions, with modest results. Medical use of marijuana smoking has bypassed traditional clinical trials...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1776610

    authors: Fragoso YD,Carra A,Macias MA

    更新日期:2020-08-01 00:00:00

  • Brivaracetam efficacy and safety in focal epilepsy.

    abstract::Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain permeability than LEV. These properties have stimulated interest in its clinical trial data and post-marketing experience. Areas covered: The authors provide a background on epilepsy and its...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1631160

    authors: Makke Y,Abou-Khalil B

    更新日期:2019-10-01 00:00:00

  • Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder.

    abstract::Initial descriptions of bipolar disorder (BD) emphasized that patients returned to a baseline condition after acute episodes. Such definitions were operational in teasing bipolar disorder apart from schizophrenia, where patients were described to be permanently impaired after the initial episodes. However, this view o...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.7.1101

    authors: Kapczinski F,Frey BN,Kauer-Sant'Anna M,Grassi-Oliveira R

    更新日期:2008-07-01 00:00:00

  • Fear reduction in patients with chronic pain: a learning theory perspective.

    abstract::Acute pain informs the individual that there is an imminent threat of body damage, and is associated with the urge to escape and avoid. Fear learning takes place when neutral stimuli receive the propensity to predict the occurrence of pain, and when defensive responses are initiated in anticipation of potential threat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.115

    authors: den Hollander M,de Jong JR,Volders S,Goossens ME,Smeets RJ,Vlaeyen JW

    更新日期:2010-11-01 00:00:00

  • Stem cell therapy for Parkinson's disease.

    abstract::The aim of stem cell therapy for Parkinson's disease is to reconstruct nigro-striatal neuronal pathways using endogenous neural stem/precursor cells or grafted dopaminergic neurons. As an alternative, transplantation of stem cell-derived dopaminergic neurons into the striatum has been attempted, with the aim of stimul...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.6.667

    authors: Takahashi J

    更新日期:2007-06-01 00:00:00

  • Genome-wide investigation of rare structural variants identifies VIPR2 as a new candidate gene for schizophrenia.

    abstract::Research has shown that structural variation in the human genome, including rare copy number variations (CNVs), contributes to genetic susceptibility to psychiatric diseases, such as schizophrenia, a devastating complex disorder with a high genetic load. The study by Vacic et al. applied a genome-wide approach to dete...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.84

    authors: Nieratschker V,Meyer-Lindenberg A,Witt SH

    更新日期:2011-07-01 00:00:00

  • An update on the comorbidity of ADHD and ASD: a focus on clinical management.

    abstract::Attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) commonly co-occur. With the DSM-5, clinicians are permitted to make an ASD diagnosis in the context of ADHD. In earlier versions of the DSM, this was not acceptable. Both ASD and ADHD are reported to have had substantial increases in pr...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2016.1146591

    authors: Antshel KM,Zhang-James Y,Wagner KE,Ledesma A,Faraone SV

    更新日期:2016-01-01 00:00:00

  • Interventions to promote the evidence-based care of children with ADHD in primary-care settings.

    abstract::Attention-deficit/hyperactivity disorder (ADHD) is a commonly occurring behavioral disorder among children. Community-based physicians are often the primary providers of services for children with ADHD. A set of consensus guidelines has been published by the American Academy of Pediatrics that provides best-practice d...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.5

    authors: Langberg JM,Brinkman WB,Lichtenstein PK,Epstein JN

    更新日期:2009-04-01 00:00:00

  • Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder.

    abstract::Attention-deficit/hyperactivity disorder (ADHD) is a highly heritable condition that affects a significant number of children and adults worldwide. During the past 30 years, the diagnosis and treatment of ADHD has relied on clinical assessment and empirical experience with stimulant medications. More recently, advance...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.4.351

    authors: Staller JA,Faraone SV

    更新日期:2007-04-01 00:00:00

  • Pharmacological therapeutics in Friedreich ataxia: the present state.

    abstract:INTRODUCTION:Friedreich ataxia (FRDA) is a progressive, inherited, neurodegenerative disease for which there is currently no cure or approved treatment. FRDA is caused by deficits in the production and expression of frataxin, a protein found in the mitochondria that is most likely responsible for regulating iron-sulfur...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1356721

    authors: Strawser C,Schadt K,Hauser L,McCormick A,Wells M,Larkindale J,Lin H,Lynch DR

    更新日期:2017-09-01 00:00:00

  • The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder.

    abstract::Pharmacotherapy, psychotherapy and other nonpharmacological interventions are used in patients with major depressive disorder (MDD). However, 50% of the patients with MDD fail to achieve a response to first-line antidepressant treatment. In four of five acute monotherapy studies, once-daily extended-release quetiapine...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.846520

    authors: Weisler R,McIntyre RS

    更新日期:2013-11-01 00:00:00

  • Electroconvulsive therapy in children and adolescents.

    abstract::Electroconvulsive therapy (ECT) is a recognized and effective treatment in adults for several psychiatric and neurological conditions in which the use of pharmacotherapy is ineffective, untimely or contraindicated. It has been used with success in mood and psychotic disorders, catatonia, neuroleptic malignant syndrome...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.178

    authors: Shoirah H,Hamoda HM

    更新日期:2011-01-01 00:00:00

  • Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

    abstract:INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, a...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1326818

    authors: Khan A,Corbett A,Ballard C

    更新日期:2017-07-01 00:00:00

  • Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.

    abstract::Alzheimer's disease is common, incurable and disabling. It is expected to grow dramatically in prevalence over the next 50 years. At current, the standard of care for patients with mild and moderately severe Alzheimer's disease includes the use of acetylcholinesterase inhibitors. Donepezil (Aricept) is a highly select...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.1.5

    authors: Geldmacher DS

    更新日期:2004-01-01 00:00:00

  • Effect of second-generation antipsychotics on cognition: current issues and future challenges.

    abstract::Generalized cognitive impairments are stable deficits linked to schizophrenia and key factors associated with functional disability in the disorder. Preclinical data suggest that second-generation antipsychotics could potentially reduce cognitive impairments; however, recent large clinical trials indicate only modest ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.143

    authors: Hill SK,Bishop JR,Palumbo D,Sweeney JA

    更新日期:2010-01-01 00:00:00

  • New-onset epilepsy: considerations for initial and follow-up MRI to detect brain tumor.

    abstract::Seizures are often the presenting symptoms of a cerebral tumor and may precede its diagnosis by many years. The article under evaluation searched two large English registries for patients admitted for new-onset epilepsy. The risk of subsequently being diagnosed with a malignant brain tumor was found to be 26-fold high...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章

    doi:10.1586/ern.11.80

    authors: Schucht P,Duffau H

    更新日期:2011-08-01 00:00:00

  • Microbiota-gut brain axis involvement in neuropsychiatric disorders.

    abstract::Introduction: The microbiota-gut brain (MGB) axis is the bidirectional communication between the intestinal microbiota and the brain. An increasing body of preclinical and clinical evidence has revealed that the gut microbial ecosystem can affect neuropsychiatric health. However, there is still a need of further studi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1638763

    authors: Iannone LF,Preda A,Blottière HM,Clarke G,Albani D,Belcastro V,Carotenuto M,Cattaneo A,Citraro R,Ferraris C,Ronchi F,Luongo G,Santocchi E,Guiducci L,Baldelli P,Iannetti P,Pedersen S,Petretto A,Provasi S,Selmer K,Sp

    更新日期:2019-10-01 00:00:00

  • Improving outcomes of subthalamic nucleus deep brain stimulation in Parkinson's disease.

    abstract::The subthalamic nucleus (STN) has been a major target of deep brain stimulation (DBS) for Parkinson's disease (PD) over the past 20 years. The benefits of DBS of the STN include: decreased motor fluctuations and bradykinesia, tremor reduction and a reduction in dopaminergic drug requirements and dyskinesias. Despite t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1081815

    authors: Bari AA,Fasano A,Munhoz RP,Lozano AM

    更新日期:2015-10-01 00:00:00

  • Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease.

    abstract::The demographics of aging identify an immediate need for the early diagnosis and development of dementia prevention strategies. Recent neuropathological studies have pointed to the early involvement of the hippocampus and entorhinal cortex in the progression of Alzheimer's disease in the brain. In particular, these st...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.4.5.831

    authors: Mosconi L,De Santi S,Rusinek H,Convit A,de Leon MJ

    更新日期:2004-09-01 00:00:00

  • Improvement of gait and balance by non-invasive brain stimulation: its use in rehabilitation.

    abstract:INTRODUCTION:Gait and balance impairments are common in many neurological disorders and among the elderly, are often difficult to treat, and have a significant effect on quality of life. Areas covered: Non-invasive brain stimulation (NIBS) technologies have been recognized for their therapeutic potential in various neu...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1564042

    authors: Ghosh S

    更新日期:2019-02-01 00:00:00

  • Cannabinoids for the treatment of multiple sclerosis: no smoke without fire?

    abstract::This review evaluates the most recent evidence available on the potential of cannabinoid drugs to relieve spasticity and pain in multiple sclerosis. Many different drugs are used to control the symptoms of multiple sclerosis, periods of relapse and the progression of the disease but it is in the potential management o...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.3.3.327

    authors: Smith PF

    更新日期:2003-05-01 00:00:00

  • Role of homocysteine in the treatment of Parkinson's disease.

    abstract::The saga of harmful administration of levodopa (LD) in the treatment of Parkinson's disease (PD) resulted from outcomes of animal trials and cell culture studies. They were initiated after the clinical observation of onset of motor complications related to the short plasma half-life of the drug in PD patients. This di...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.6.957

    authors: Müller T

    更新日期:2008-06-01 00:00:00

  • Update on the treatment of vitamin B6 dependent epilepsies.

    abstract::Introduction: Vitamin B6 dependent epilepsies are a group of treatable diseases (ALDH7A1 deficiency, PNPO deficiency, PLP binding protein deficiency, hyperprolinaemia type II and hypophosphatasia and glycosylphosphatidylinositol anchor synthesis defects) responding to pyridoxine or pyridoxal-5I-phosphate. Areas covere...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1648212

    authors: Mastrangelo M,Cesario S

    更新日期:2019-11-01 00:00:00

  • No evidence of disease activity in multiple sclerosis patients.

    abstract:INTRODUCTION:Multiple Sclerosis is a chronic inflammatory demyelinating disease that affects 2.5 million people in the world. NEDA (No evidence of disease Activity) -4 is a new concept related to absence of disease activity in the context of MS. It takes into account the following four parameters: relapses; disability ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1202763

    authors: Matta AP,Nascimento OJ,Ferreira AC,Magalhães TN,Benevides TP,Kirmse A,Dib JG,Cal H,Orsini M,Araujo LM

    更新日期:2016-11-01 00:00:00

  • Clinical, etiological and therapeutic aspects of cerebral folate deficiency.

    abstract::Cerebral folate deficiency is defined as any neurological condition associated with low cerebrospinal fluid folate concentrations. It is becoming increasingly associated with several neurological diseases, either genetic or environmental. Treatment of cerebral folate deficiency by folate supplementation is generally e...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1055322

    authors: Molero-Luis M,Serrano M,O'Callaghan MM,Sierra C,Pérez-Dueñas B,García-Cazorla A,Artuch R

    更新日期:2015-01-01 00:00:00

  • Metacognitions in generalized anxiety disorder: theoretical and practical perspectives.

    abstract::Cognitive behavioral therapy has been found to be efficacious in the treatment of generalized anxiety disorder (GAD). However, reviews of the clinical significance has indicated that approximately 50% of patients with GAD return to a 'well' status following treatment. So how might the field advance? One way is to base...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.161

    authors: Heiden Cv

    更新日期:2013-02-01 00:00:00

  • Precision medicine in genetic epilepsies: break of dawn?

    abstract:INTRODUCTION:Therapy with current antiepileptic drugs aims at reducing the likelihood of seizure occurrence rather than influencing the underlying disease process. Therefore, antiepileptic drugs have an anticonvulsant rather than antiepileptic property. Areas covered: The increasing identification of genetic causes for...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1253476

    authors: Reif PS,Tsai MH,Helbig I,Rosenow F,Klein KM

    更新日期:2017-04-01 00:00:00

  • Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas.

    abstract::Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas. Notwithstanding a survival benefit in a subset of patients with high-grade gliomas, temozolomide (TMZ; Temodar®, Schering-Plough Pharmaceuticals, NJ, USA) is the primarily palliative treatment fo...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.32

    authors: Chamberlain MC

    更新日期:2010-10-01 00:00:00

  • Adverse effects in the treatment of Parkinson's disease.

    abstract::Side effects to antiparkinsonian drugs constitute an important component of the daily management of patients with Parkinson's disease. Treatment with levodopa frequently leads to motor fluctuations and dyskinesias. Hallucinosis, nausea and vomiting, drowsiness, orthostatic hypotension and peripheral edema can be manag...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.1.105

    authors: Singer C

    更新日期:2002-01-01 00:00:00